BURLINGTON, Mass.–PAQ Therapeutics has reported initial clinical results from an ongoing Phase 1 trial of PT0253, an experimental cancer drug designed to selectively degrade the KRAS G12D mutant protein, showing early antitumor activity in patients with advanced solid tumors and a favorable preliminary safety profile.
The findings were presented by Alexander I. Spira, M.D., Ph.D., FACP, FASCO, of NEXT Oncology Virginia, during a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.
The Burlington-based biotechnology company is developing PT0253 as a targeted protein degradation therapy for cancers driven by KRAS mutations, including pancreatic, colorectal and lung cancers.
According to the company, the initial results showed no dose-limiting toxicities across the tested dose range, along with evidence of antitumor activity in patients receiving PT0253 alone or in combination with standard chemotherapy.
As of October 23, 2026, the Phase 1 trial had enrolled 44 patients with KRAS G12D-mutant advanced solid tumors who received weekly intravenous doses of PT0253 ranging from 10 to 750 milligrams.
Patients had previously received a median of 2.5 lines of treatment, while 27% had been treated with KRAS-targeted or related therapies.
No dose-limiting toxicities were observed across the tested dose levels. Among 27 patients receiving doses between 120 and 750 milligrams, most treatment-related adverse events were mild or moderate.
One patient, representing 4% of that group, experienced a Grade 3 or higher treatment-related adverse event. No serious treatment-related adverse events or treatment discontinuations due to treatment-related adverse events were reported.
The company also noted that PT0253 did not require drug-specific preventive medication before administration.
Early evidence of antitumor activity was observed across several cancer types.
Among six patients with treatment-resistant colorectal cancer who received doses of at least 120 milligrams, three experienced partial tumor responses, although those responses had not yet been confirmed.
One of those patients had previously experienced disease progression while receiving a KRAS-targeted therapy.
In pancreatic cancer, three of ten patients who had not previously received KRAS-targeted treatment achieved confirmed partial responses. Nine of the ten patients experienced disease control, indicating that their tumors either shrank or remained stable during treatment.
Among 12 patients whose cancers had progressed following previous KRAS-targeted or related therapies, six achieved disease control.
The company said these findings suggest PT0253 may have activity in some patients whose cancers have developed resistance to existing targeted treatments, although additional clinical testing is needed.
PAQ Therapeutics also reported preliminary results from a separate group of patients receiving PT0253 in combination with modified FOLFIRINOX, a standard chemotherapy regimen used to treat metastatic pancreatic cancer.
Fourteen patients received 350 milligrams of PT0253 once weekly alongside chemotherapy, with 13 remaining on treatment as of the October 23 data cutoff.
Among seven patients who had undergone at least two follow-up imaging scans, six achieved objective tumor responses.
These included one confirmed complete response and five partial responses, four of which were confirmed.
The company reported that the combination was generally well tolerated, with a safety profile consistent with chemotherapy alone. Gastrointestinal toxicity was low, and patients did not require PT0253-specific preventive treatment.
The median relative dose intensity was 91% for PT0253, while the chemotherapy components were administered at 75% to 80% of their planned doses, consistent with expectations for the regimen.
“We are encouraged by these initial clinical data for PT0253. Its differentiated safety profile, monotherapy antitumor activity and promising early combination results support our strategy of advancing KRAS protein degradation as a new therapeutic approach,” said Nan Ji, Ph.D., Chief Executive Officer of PAQ Therapeutics. “We look forward to further evaluating PT0253 in pancreatic and colorectal cancer expansion cohorts.”
Andrew P. Krivoshik, M.D., Chief Medical Officer of PAQ Therapeutics, said the findings suggest the experimental therapy could be administered alongside existing chemotherapy regimens.
“PT0253 as a monotherapy was well tolerated across the full dose range without pre-treatment prophylaxis. Importantly, in combination with mFOLFIRINOX in first-line pancreatic cancer, patients received chemotherapy at its expected relative dose intensity,” said Krivoshik. “With no dose-limiting toxicities and a high rate of deep responses, the first-line combination data are an important demonstration of combinability with standard-of-care therapy.”
Spira said the preliminary results were particularly noteworthy among patients whose cancers had progressed despite previous treatments.
“Patients with KRAS G12D-mutant cancers who progress on chemotherapy, and increasingly on KRAS-targeted therapies, have few options,” said Dr. Spira. “It is encouraging to see antitumor activity, including a partial response and disease control, in patients whose disease had progressed on prior (K)RAS-targeted therapy. The favorable tolerability observed across the dose range and in combination with standard-of-care chemotherapy is also encouraging. The expansion cohorts will be important to further evaluate these early findings.”
PT0253 is an investigational small-molecule therapy administered intravenously that is designed to selectively eliminate the KRAS G12D mutant protein, which plays a role in the growth and progression of several cancers.
Unlike conventional KRAS inhibitors, which block the activity of the target protein, PT0253 is designed to degrade the protein itself, potentially providing sustained suppression of cancer-driving signals.
The ongoing Phase 1 trial is evaluating the drug’s safety, tolerability and optimal dosing in adults with advanced solid tumors carrying the KRAS G12D mutation.
PAQ Therapeutics plans to continue evaluating PT0253 in expanded pancreatic and colorectal cancer patient groups to further assess its potential effectiveness and safety.
The results remain preliminary, and larger clinical studies will be needed to determine whether the treatment provides sustained benefits for patients.


